Cory Renauer
Value, research analyst, biotech, small-cap

Sarepta And Eteplirsen: Will 12 Patients Be Enough For The FDA?

Sarepta Therapeutics (NASDAQ:SRPT) creates RNA-based drugs for the treatment of serious and life threatening diseases. Its most advanced candidate is an intravenously delivered treatment for Duchenne Muscular Dystrophy [DMD]. In addition to the promising DMD program, the company also has drugs for the treatment of ebola, Marburg and influenza viruses in clinical Phase 1 trials.

RNA drugs without the R

The company uses a phosphorodiamidate morpholino oligomer [PMO] antisense platform that allows for a diverse range of therapeutic candidates. The technology is far simpler than its name implies. Natural RNA is a string of nucleic acid bases (adenine, cytosine, guanine, and thymine) held together by backbone of recurring ribose rings. Sarepta's PMOs use the same nucleic acid bases,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details